|本期目录/Table of Contents|

[1]仇丽霞,胡中杰,林伟,等.半量索非布韦联合达卡他韦治疗透析患者慢性丙型肝炎的疗效及安全性研究[J].慢性病学杂志,2017,(07):727-730.
　QIU Li-xia*,HU Zhong-jie,LIN Wei,et al.Study on efficacy and safety of half-dose sofosbuvir and full dose daclatasvir in treatment of chronic hepatitis C in hemodialysis patients[J].,2017,(07):727-730.
点击复制

半量索非布韦联合达卡他韦治疗透析患者慢性丙型肝炎的疗效及安全性研究(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2017年07期
页码:
727-730
栏目:
论著
出版日期:
2017-08-08

文章信息/Info

Title:
Study on efficacy and safety of half-dose sofosbuvir and full dose daclatasvir in treatment of chronic hepatitis C in hemodialysis patients
作者:
仇丽霞1; 胡中杰1; 林伟1; 范文俊2; 张晶1; 金荣华1
1. 首都医科大学附属北京佑安医院丙肝与中毒性肝病科，北京100069 2. 杭州永珍万泰医院管理咨询有限公司，杭州310001
Author(s):
QIU Li-xia*;  HU Zhong-jie;  LIN Wei;  FAN Wen-jun;  ZHANG Jing;  JIN Rong-hua
*Beijing Youan Hospital, Capital Medical University, Beijing 100069, China Corresponding author: ZHANG Jing, E-mail: drzhangjing@163.com
关键词:
丙型肝炎; 直接抗病毒药; 肾功能衰竭; 索非布韦; 达卡他韦
Keywords:
Hepatitis C;  Direct antivirallagents;  Renal failure;  Sofosbuvir;  Daclatasvir
分类号:
R512.6
DOI:
-
摘要:
目的观察并探讨半量索非布韦联合达卡他韦治疗透析患者慢性丙型肝炎的疗效及安全性。方法规律 透析患者合并慢性丙型肝炎39 例，其中丙肝基因型1 型8 例。给予索非布韦半量联合达卡他韦常规剂量在透析结 束时服用，疗程24 周。观察停药后12 周HCV 应答率并记录不良反应。结果治疗2 周时HCV-RNA 阴转率 （<15 IU/ml） 为28例（71.8%），停药后12周病毒学应答率为100%。无因不良反应停药或减量患者。ALT/AST 在治疗后显著下降，16 例患者出现了HGB 降低，平均降低（14.3±17.4） g/L，其中2 例降低50 g/L 以上。结 论半量索非布韦联合达卡他韦治疗透析患者慢性丙型肝炎具有良好的疗效及安全性。
Abstract:
Objective To evaluate the effectiveness and safety with half-dose sofosbuvir and full dose daclatasvir for hepatitis C in hemodialysis patients. Method A total of 39 patients on regular hemodialysis with positive HCV-RNA were included, and 8 patients were genotype 1. Half-dose sofosbuvir and full dose daclatasvir were used at the end of hemodialysis for 24 weeks. Sustained viral response at 12 weeks, biochemistry results and side effects were recorded. Results HCV-RNA decreased to below 15 IU/ml in 2 weeks in 28 patients. Rate of sustained viral response in 12 week was 100%. No patients stopped treatment or reduced dosage due to side effect. ALT and AST decreased significantly after treatment. Hemoglobin decreases were found in 16 patients with more than 50 g/L in 2 cases, and the average of hemoglobin decreases was (14.3±17.4) g/L. Conclusion Treatment of halfdose sofosbuvir and full dose daclatasvir was effective and safe for hepatitis C in hemodialysis patients.

参考文献/References:

[1] Bhamidimarri KR, Czul F, Peyton A, et al. Safety, efficacy and tolerability of half- dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease [J]. J Hepatol, 2015,63(3):763.
[2] Cholongitas E, Pipili C, Papatheodoridis GV. Interferonfree regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation [J]. World J Hepatol, 2017,9(4):180.
[3] Reese PP, Abt PL, Blumberg EA, et al. Transplanting hepatitis C- positive kidneys [J]. N Engl J Med, 2015,373 (4):303.
[4] Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant [J]. J Hepatol, 2007,46(5):768-774.
[5] Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment- naive and treatment- experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study [J]. The Lancet, 2015,386 (10003):1537-1545.
[6] Deeks ED. Ombitasvir/paritaprevir/ritonavir plus dasabuvir: a review in chronic HCV genotype 1 infection [J]. Drugs, 2015,75(9):1027-1038.
[7] 丙型肝炎防治指南(2015 年更新版)[J]. 传染病信息,2016,29(1): 1-19.
[8] EASL Recommendations on Treatment of Hepatitis C 2015 [J]. J Hepatol, 2015,63(1):199-236.
[9] De Nicola S, Aghemo A. The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment [J]. Liver Int, 2016,36(6):791-793.
[10] Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir- based regimen given daily in hemodialysis patients with chronic hepatitis C [J]. J Hepatol, 2016,65(1):40-47.
[11] Dumortier J, Bailly F, Pageaux GP, et al. Sofosbuvirbased antiviral therapy in hepatitis C virus patients with severe renal failure [J]. Nephrol Dial Transplant, 2016:348.
[12] Li T, Qu Y, Guo Y, et al. Efficacy and safety of directacting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a metaanalysis [J]. Liver Int, 2017,37(7):974-981.

备注/Memo

备注/Memo:

作者简介：仇丽霞，本科，主治医师，主要从事肝脏疾病 的临床和基础研究工作
通信作者：张晶，E-mail: drzhangjing@163.com
更新日期/Last Update: 2017-08-18